P - Caution when used during pregnancy
FI - Food *
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names AcipHex in the US, Pariet in Japan and Canada, & Rablet in India.
Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting the gastric H+/K+ ATPase at the secretory surface of the gastric parietal cell.
Onset
1 hour.
Duration
24 hours
Absorption
Oral bioavailability: about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin.
Distribution
Protein-binding: 97%.
Metabolism
Extensively metabolised in the liver by cytochrome P450 isoenzymes.
Excretion
Metabolites are mainly excreted in the urine (90%). Half-life: about 1 hour.
Information Not Available
Headache, diarrhoea, rash, infection and flu-like syndrome. Dizziness, fatigue, constipation, nausea and vomiting.
Potentially Fatal: Anaphylaxis, agranulocytosis.
Information Not Available
Severe hepatic impairment, gastric malignancy. May increase the risk of GI infections due to acid suppressive effects. Pregnancy.
May reduce absorption of ketoconazole and itraconazole. May prolong the elimination of diazepam, phenytoin and warfarin.
Food Interaction
Delayed absorption with high-fat meals.
Oral
Gastro-oesophageal reflux disease
Adult: For erosive oesophagitis: 20 mg once daily in the morning for 4-8 wk. Maintenance: 10-20 mg once daily according to response. For non-erosive oesophagitis: 10 mg once daily for 4 wk, upon symptom resolution, may continue with 10 mg once daily when necessary.
Oral
Hypersecretory conditions
Adult: Initially, 60 mg daily adjusted according to response. Max dose: 120 mg daily.
Oral
Active peptic ulcer disease
Adult: 20 mg daily given for 4-8 wk for duodenal ulcer and 6-12 wk for gastric ulcer.
Oral
H.pylori infection
Adult: As a combination with two antibacterials: 20 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid. To be taken for a week.
Delayed-release: May be taken with or without food.
Caution when used during pregnancy.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Undetermined
Safety and efficacy not established in the short-term treatment of GERD in children younger than 12 yr of age. For other indications, safety and efficacy not established.
Information Not Available
Hypersensitivity
Oral
Store at 15-30°C
Oral
Store at 15-30°C
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.